# JAGSONPAL PHARMACEUTICALS LIMITED

Regd. office : T-210 J, Shahpur Jat, New Delhi-110 049 (INDIA)
Fax : 0091-11-26498341,26494708, Phone: 0091-11-26494519-24
E-mail: admin@jagsonpal.com

1. The Bombay Stock Exchange Limited, Mumbai
2. The National Stock Exchange of India Ltd., Mumbai

Fax 022-22723121, 22722037, 22723719, 22722041
Fax 022- 26598237, 38


**Unaudited Financial Results for the Quarter ended 31.12.2010**

(Rs. in lacs)

| Particulars | Quarter ended 31.12.2010 Unaudited | Quarter ended 31.12.2009 Unaudited | 9 Months ended 31.12.2010 Unaudited | 9 Months ended 31.12.2009 Unaudited | 12 Months ended 31.03.2010 Audited |
|---|---|---|---|---|---|
| 1(a) Net sales/Income from Operations | 4209.39 | 3230.38 | 12909.97 | 10001.58 | 13959.34 |
| 1(b) Other Operating Income | | | | | |
| Total | 4209.39 | 3230.38 | 12909.97 | 10001.58 | 13959.34 |
| 2 Expenditure | | | | | |
| a. (Inc.)/Dec. in Stock in trade and work in progress | 39.31 | -84.58 | 835.80 | -810.71 | -1042.09 |
| b. Consumption of Raw Materials | 1925.61 | 1308.42 | 5052.13 | 4788.96 | 7219.40 |
| c. Purchase of traded goods | 236.18 | 308.95 | 802.89 | 1352.91 | 1372.92 |
| d. Employees Cost | 886.38 | 649.41 | 2472.57 | 1774.69 | 2378.78 |
| e. Depreciation | 51.34 | 50.05 | 166.45 | 149.88 | 208.50 |
| f. Other Expenditure | 860.33 | 649.37 | 2447.93 | 1831.48 | 2458.50 |
| g. Total | 3999.15 | 2881.62 | 11777.77 | 9087.21 | 12596.01 |
| 3 Profit from Operations before Other Income, Interest and Exceptional Items (1-2) | 210.24 | 348.76 | 1132.20 | 914.37 | 1363.33 |
| 4 Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 36.30 |
| 5 Profit before Int.& Exceptional Items (3+4) | 210.24 | 348.76 | 1132.20 | 914.37 | 1399.63 |
| 6 Interest | 95.13 | 87.87 | 281.46 | 255.74 | 349.62 |
| 7 Profit After Interest but before Exceptional items (5 - 6) | 115.11 | 260.89 | 850.74 | 658.63 | 1050.01 |
| 8 Exceptional Items | | | | | |
| 9 Profit(+)/Loss(-) from Ordinary Activities before tax (7 +8) | 115.11 | 260.89 | 850.74 | 658.63 | 1050.01 |
| 10 Tax expense | 37.00 | 20.00 | 172.00 | 100.00 | 125.81 |
| 11 Net Profit(+)/Loss(-) from Ordinary Activities after tax (9-10) | 78.11 | 240.89 | 678.74 | 558.63 | 924.20 |
| 12 Extraordinary Items (net of tax expense) | | | | | |
| 13 Net Proft (+)/ Loss (-) for the period (11-12) | 78.11 | 240.89 | 678.74 | 558.63 | 924.20 |
| 14 Paid up Eq. Sh. Cap.(Face value Rs. 5) | 1309.90 | 1309.90 | 1309.90 | 1309.90 | 1309.90 |
| 15 Reserves excluding Revaluation reserves as per Balance sheet of pr. accounting yr. | | | | | 6049.30 |
| 16 Earnings Per Share (EPS) | | | | | |
| a. Basic & diluted EPS before extraordinary items for the period. | 0.30 | 0.92 | 2.59 | 2.13 | 3.53 |
| b. Basic & diluted EPS after extraordinary items for the period. | 0.30 | 0.92 | 2.59 | 2.13 | 3.53 |
| 17 Public shareholding : | | | | | |
| - Number of shares | 8962360 | 8962360 | 8962360 | 8962360 | 8962360 |
| - Percentage of Shareholding | 34.21% | 34.21% | 34.21% | 34.21% | 34.21% |
| 18 Promoter and promoter group shareholding | | | | | |
| a. Pledged / Encumbered | | | | | |
| - Number of shares | - | - | - | - | - |
| - Percentage of shares (as a % of the total shareholding of promoter and promoter group) | - | - | - | - | - |
| - Percentage of shares (as a % of the total share capital of the Company) | - | - | - | - | - |
| b. Non - encumbered | | | | | |
| - Number of shares | 17235640 | 17235640 | 17235640 | 17235640 | 17235640 |
| - Percentage of shares (as a % of the total shareholding of promoter and promoter group) | 100% | 100% | 100% | 100% | 100% |
| - Percentage of shares (as a % of the total share capital of the Company) | 65.79% | 65.79% | 65.79% | 65.79% | 65.79% |

Notes

1. The Financial Results for the Quarter ended 31.12.2010 have been reviewed by the Auditors as well as Audit Committee. The Board of Directors has taken on record the financial Results at its meeting held on 11-2-2011
2. No complaints were pending at the beginning/end of the quarter ended 31.12.2010. However 67 requests for change of address/ dividend revalidation/Annual Reports etc. were received & promptly responded to during the quarter.
3. The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
4. The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.

By Order of the Board
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar
Managing Director

Place : New Delhi
Date : 11.2.2011